Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fougera Pharmaceuticals Inc.

Division of Novartis AG
www.nycomedus.com

Latest From Sandoz International GMBH

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go

Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.

Emerging Markets Intellectual Property

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

Turkish Industry Group Builds New Platform To Support Biotech

A major local pharmaceutical industry group in Turkey is leading the formation of a new biotechnology platform that will focus on lobbying the government to create a more friendly investment environment, and promote joint projects and training. Given ongoing official moves to attract investments in the pharma and biotech field, the initiative appears to align well with broader existing policies.

Turkey Biologics
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register